Toronto, Canada (PRWEB) March 08, 2013
With patient recruitment rates up to twenty times faster than the West, the biopharmaceutical industry is embracing the undeniable benefits of conducting clinical trials in emerging markets such as Russia. In fact, 33% of all drugs approved by the FDA and 48% of all drugs approved by the EMEA in 2011 included data from clinical trial research conducted in this region.
Yet with benefits like this, why isn’t this number closer to 100%? For many, the enticement for conducting clinical trials in emerging markets is over shadowed by the fear of unknown regulatory and logistics requirements, prolonged study start-up times and overall clinical trial quality.
During the webinar, ClinStar CEO David Passov and QA Director Dr. Stanislav Gneushev will evaluate the quality of clinical trials being conducted in Russia / Ukraine compared to Western Europe, Eastern Europe and other Emerging Markets based on the results of recent FDA inspections conducted at clinical trial sites in these regions. In addition, they will:
For more information about this event or to register, visit: http://xtks.in/xto580-event
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx
Karen Lim (416) 977-6555 ext 227
Read the full story at http://www.prweb.com/releases/2013/3/prweb10499405.htm.
Copyright©2012 Vocus, Inc.
All rights reserved